(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'It's doing badly': Fears grow for whale stuck off Germany's coast - 2Trial of pro-Palestine activist begins
- 3Coffee Prices Finish Higher on Brazil Cop Concerns
- 4Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- 5As world leaders enter climate talks, people in poverty have the most at stake
- Help Your Business with Master Web based Promoting Arrangements
- Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024
- Shelby County deputies charged with assault, placed on leave
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- Truly amazing Palaces: Which Is Your Number one?
- Nutrient Rich Natural products: Lift Your Wellbeing
- Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
